ID
32557
Description
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma
Keywords
Versions (2)
- 11/6/18 11/6/18 -
- 12/6/18 12/6/18 -
Copyright Holder
GSK group of companies
Uploaded on
November 6, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837
Study conclusion
- StudyEvent: ODM
Description
If YES, complete primary reason for withdrawal
Description
record details on AE or SAE forms as appropriate)
Data type
boolean
Description
Check all that apply. If none, select "No Subreasons"
Data type
text
Description
Check all that apply. If none, select "No Subreasons"
Data type
text
Description
4. Subject reached protocol defined stopping criteria
Data type
text
Description
5. Study closed/terminated
Data type
boolean
Description
6. Lost to Follow-Up
Data type
boolean
Description
Select this reason if none of the other primary reasons are appropriate
Data type
text
Description
Select this reason if none of the other primary reasons are appropriate
Data type
text
Similar models
Study conclusion
- StudyEvent: ODM